HONG KONG, June 19, 2025 /PRNewswire/ — Immuno Cure BioTech (“Immuno Cure“), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via PharmaJet’s innovative Tropis® needle-free injection system in a clinical study. On June 16, 2025, Immuno Cure and PharmaJet held a material transfer agreement (“MTA“) signing ceremony at the BIO 2025 International Convention in Boston, USA to commemorate such collaboration.
From left to right: Mr. Derek CHIM, Head of Startup Ecosystem and Development of Hong Kong Science and Technology Parks Corporation; Ms. Priscilla CHIU, Associate Director of the New Ventures Development of Hong Kong Science and Technology Parks Corporation; Ms. Weng-Li YOON, Associate Director of Life and Health Technology (Therapeutics) of Hong Kong Science and Technology Parks Corporation; Dr. Xia JIN, CEO and Co-Founder of Immuno Cure; Mr. Dan MALLON, Senior Vice President of Corporate Development of PharmaJet; Professor Zhiwei CHEN, Director of AIDS Institute and Chair Professor of the Department of Microbiology of the University of Hong Kong, and Principal Scientific Advisor of Immuno Cure; Ms. Hong GE, General Manager of Beijing Immuno Cure & Assistant to Group CEO; Dr. Steve CHONG, Senior Manager of Life and Health Technology (Therapeutics), of Hong Kong Science and Technology Parks Corporation.It captured the memorable moment after signing the MTA ” HIV Therapeutic DNA Vaccine (ICVAX) Clinical Study”
HIV/AIDS remains a critical global health challenge today, despite advances in treatment and prevention. As of 2023, over 39 million people were living with HIV, and more than 40 million deaths have occurred since the start of the epidemic in 1981. Current antiretroviral therapy (“ART“) is highly effective in suppressing the virus in HIV-1 infected individuals, but it does not provide a cure. This underscores the necessity for an effective immunotherapy that can enhance the host immune response to establish a state of ART-free virological control, or a functional cure.
ICVAX employs Immuno Cure’s patented PD-1-Enhanced DNA Vaccine technology, which aims to achieve sustained, immune-mediated HIV-1 virological control without the need of ART. Following the successful first-in-human ICVAX Phase I clinical trial that showed exceptional safety and immunogenicity profiles, this new clinical study will explore the use of the WHO prequalified PharmaJet Tropis device for the administration of ICVAX, which allows precise intradermal delivery through its advanced needle-free technology. Tropis’ global regulatory clearances and manufacturing scale reduce development risk and may improve the DNA vaccine performance and patient’s clinical experience.
This study will be conducted at Prince of Wales Hospital in Hong Kong SAR, led by Professor Grace LUI, Head of the Division of Infectious Diseases at the Faculty of Medicine, the Chinese University of Hong Kong (“CUHK“). This study is a collaborative effort among Immuno Cure, CUHK, and the AIDS Institute of the University of Hong Kong, and is partially supported by the funding from the Public Sector Trial Scheme of the Innovation and Technology Commission of the HKSAR Government. Professor Zhiwei CHEN, Director of the AIDS Institute of the University of Hong Kong, serves as the Project Coordinator for this funding.
Dr. Xia JIN MD PhD, CEO of Immuno Cure, said “We are thrilled to partner with PharmaJet on this innovative delivery approach to HIV treatment. This collaboration not only advances needle-free vaccination solutions but also accelerates the global commercialization potential for ICVAX and the vaccine’s ability to transform HIV management.”
Mr. Dan MALLON, Senior Vice President of Corporate Development of PharmaJet, added “We are excited to support Immuno Cure’s novel HIV-1 therapeutic vaccine program with PharmaJet’s patented needle-free injection technology. PharmaJet is one of the leaders in nucleic acid-based vaccine and therapeutic delivery and we are encouraged by the potential for the Tropis intradermal delivery system to make a substantial impact for HIV patients. This partnership reflects our shared commitment to advancing innovative, patient-friendly technologies that address unmet medical needs globally.”
Immuno Cure and PharmaJet are committed to pioneering new frontiers in vaccine delivery and enhancing patient experiences through cutting-edge technologies.
About Immuno Cure
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms.
To learn more about Immuno Cure, please visit: www.immunocure.hk
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs.
To learn more about PharmaJet, please visit: https://pharmajet.com/
SOURCE Immuno Cure Holding (HK) Limited
